ANG Lifesciences India has acquired two formulation manufacturing facilities from Ind-Swift for Rs 60 crores payable through internal accrual & bank funding on a deferred payment basis up to 30-Jun-2024, located at Baddi (HP). The plants are now running as Unit 5 & Unit 6 of ANG Lifesciences India respectively. The said acquisition has helped in scaling up ANG's manufacturing capacity to meet the growing demand from domestic as well as international markets.

This acquisition is in line with ANG's long-term strategic objective to become a complete healthcare solution provider aimed at creating a broad-based basket of pharmaceutical formulation products for a differentiated and comprehensive profile in pharmaceutical markets.

The Plant (Unit 3 of Ind-Swift Limited) is located adjacent to ANG's flagship plant spread over an area of 2.85 acres and has a state of the art facility for formulation manufacturing comprising over two lakh square feet covered area and has different manufacturing formulations with integrated utilities.

The company expects a potential sales turnover of Rs.350-500 crores with a 100% capacity utilization basis from this plant.

The plant (Unit 4 of Ind-Swift Limited) is located adjacent to ANG's flagship plant spread over an area of 7.2 acres having a state of the art facility for formulation manufacturing comprising more than one lakh square foot area and having different manufacturing formulations with integrated utilities.

The company expects a potential sales turnover of Rs.100-120 crores with a 100% capacity utilization basis from this plant. This unit has surplus land available for setting up new formulation facilities and for further expansion.